CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Open-Label Study of the Intravenous Administration of Homoharringtonine (CGX-635) Combined With the Oral Administration of Gleevec in the Treatment of Patients With Chronic Myeloid Leukemia (CML) in Chronic, Accelerated, and Blast Phase

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00114959
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:46.168988+00:00
Published At: 2015-01-15T00:00:00+00:00
Record Updated At: 2015-01-15
Results Posted At: 2015-01-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Myeloid Leukemia, Chronic", "Myeloid Leukemia, Chronic, Accelerated-Phase", "Blast Phase", "Myeloid Leukemia, Chronic, Chronic-Phase"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2015-01-15"
protocolSection.identificationModule.nctId: "NCT00114959"
protocolSection.identificationModule.officialTitle: "A Phase II Open-Label Study of the Intravenous Administration of Homoharringtonine (CGX-635) Combined With the Oral Administration of Gleevec in the Treatment of Patients With Chronic Myeloid Leukemia (CML) in Chronic, Accelerated, and Blast Phase"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2015-01-15"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.